BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

667 related articles for article (PubMed ID: 20679668)

  • 21. Long-term mortality after bolus-only administration of abciximab, eptifibatide, or tirofiban during percutaneous coronary intervention.
    Marmur JD; Poludasu S; Lazar J; Cavusoglu E
    Catheter Cardiovasc Interv; 2009 Feb; 73(2):214-21. PubMed ID: 19156882
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Intracoronary compared to intravenous Abciximab and high-dose bolus compared to standard dose in patients with ST-segment elevation myocardial infarction undergoing transradial primary percutaneous coronary intervention: a two-by-two factorial placebo-controlled randomized study.
    Bertrand OF; Rodés-Cabau J; Larose E; Rinfret S; Gaudreault V; Proulx G; Barbeau G; Déry JP; Gleeton O; Manh-Nguyen C; Noël B; Roy L; Costerousse O; De Larochellière R;
    Am J Cardiol; 2010 Jun; 105(11):1520-7. PubMed ID: 20494655
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Increase of myocardial salvage and left ventricular function recovery with intracoronary abciximab downstream of the coronary occlusion in patients with acute myocardial infarction treated with primary coronary intervention.
    Bellandi F; Maioli M; Gallopin M; Toso A; Dabizzi RP
    Catheter Cardiovasc Interv; 2004 Jun; 62(2):186-92. PubMed ID: 15170708
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Early abciximab administration before primary percutaneous coronary intervention improves clinical outcome in diabetic patients with ST-segment elevation myocardial infarction (EUROTRANSFER Registry).
    Dziewierz A; Mielecki W; Siudak Z; Rakowski T; Janzon M; Birkemeyer R; Zasada W; Dubiel JS; Dudek D
    Atherosclerosis; 2012 Jul; 223(1):212-8. PubMed ID: 22658254
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Predictors and implications of coronary infarct artery patency at initial angiography in patients with acute myocardial infarction (from the CADILLAC and HORIZONS-AMI Trials).
    Brener SJ; Mehran R; Brodie BR; Guagliumi G; Witzenbichler B; Cristea E; Xu K; Lansky AJ; Stone GW
    Am J Cardiol; 2011 Oct; 108(7):918-23. PubMed ID: 21764028
    [TBL] [Abstract][Full Text] [Related]  

  • 26. A multicenter randomized study to evaluate intracoronary abciximab with the ClearWay catheter to improve outcomes with Lysis (IC ClearLy): trial study design and rationale.
    Sardella G; Sangiorgi GM; Mancone M; Colantonio R; Donahue M; Politi L; Bucciarelli-Ducci C; Carbone I; Francone M; Ligabue G; Fiocchi F; Di Roma A; Benedetti G; Lucisano L; Stio RE; Agati L; Modena MG; Genuini I; Fedele F; Gibson M
    J Cardiovasc Med (Hagerstown); 2010 Jul; 11(7):529-35. PubMed ID: 19918189
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Intracoronary versus intravenous administration of abciximab in patients with ST-segment elevation myocardial infarction undergoing primary percutaneous coronary intervention with thrombus aspiration: the comparison of intracoronary versus intravenous abciximab administration during emergency reperfusion of ST-segment elevation myocardial infarction (CICERO) trial.
    Gu YL; Kampinga MA; Wieringa WG; Fokkema ML; Nijsten MW; Hillege HL; van den Heuvel AF; Tan ES; Pundziute G; van der Werf R; Hoseyni Guyomi S; van der Horst IC; Zijlstra F; de Smet BJ
    Circulation; 2010 Dec; 122(25):2709-17. PubMed ID: 21098442
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Benefits from intracoronary as compared to intravenous abciximab administration for STEMI patients undergoing primary angioplasty: a meta-analysis of 8 randomized trials.
    De Luca G; Verdoia M; Suryapranata H
    Atherosclerosis; 2012 Jun; 222(2):426-33. PubMed ID: 22483166
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Intracoronary eptifibatide bolus administration during percutaneous coronary revascularization for acute coronary syndromes with evaluation of platelet glycoprotein IIb/IIIa receptor occupancy and platelet function: the Intracoronary Eptifibatide (ICE) Trial.
    Deibele AJ; Jennings LK; Tcheng JE; Neva C; Earhart AD; Gibson CM
    Circulation; 2010 Feb; 121(6):784-91. PubMed ID: 20124127
    [TBL] [Abstract][Full Text] [Related]  

  • 30. PCI with and without abciximab after upstream eptifibatide use: outcomes in high-risk patients.
    Applegate RJ; Grabarczyk MA; Sane DC; Sacrinty MT; Goodin JE; Statonk GS; Baki TT; Gandhi SK; Kutcher MA; Little WC
    J Invasive Cardiol; 2006 Dec; 18(12):604-13. PubMed ID: 17197712
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Intracoronary compared with intravenous bolus abciximab application in patients with ST-elevation myocardial infarction undergoing primary percutaneous coronary intervention: the randomized Leipzig immediate percutaneous coronary intervention abciximab IV versus IC in ST-elevation myocardial infarction trial.
    Thiele H; Schindler K; Friedenberger J; Eitel I; Fürnau G; Grebe E; Erbs S; Linke A; Möbius-Winkler S; Kivelitz D; Schuler G
    Circulation; 2008 Jul; 118(1):49-57. PubMed ID: 18559698
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Achieved platelet aggregation inhibition after different antiplatelet regimens during percutaneous coronary intervention for ST-segment elevation myocardial infarction.
    Ernst NM; Suryapranata H; Miedema K; Slingerland RJ; Ottervanger JP; Hoorntje JC; Gosselink AT; Dambrink JH; de Boer MJ; Zijlstra F; van 't Hof AW
    J Am Coll Cardiol; 2004 Sep; 44(6):1187-93. PubMed ID: 15364318
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Administration of eptifibatide during transfer for primary PCI in patients with STEMI: effect on Pre-PCI TIMI flow and its correlation with pain-to-therapy time.
    Aquilina M; Varani E; Balducelli M; Vecchi G; Frassineti V; Maresta A
    J Invasive Cardiol; 2009 Mar; 21(3):115-20. PubMed ID: 19258642
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Intracoronary versus intravenous bolus abciximab administration in patients undergoing primary percutaneous coronary intervention with acute ST-elevation myocardial infarction: a pooled analysis of individual patient data from five randomised controlled trials.
    Piccolo R; Eitel I; Iversen AZ; Gu YL; Dominguez-Rodriguez A; de Smet BJ; Mahmoud KD; Abreu-Gonzalez P; Thiele H; Piscione F
    EuroIntervention; 2014 Jan; 9(9):1110-20. PubMed ID: 24457282
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Prediction of 1-year clinical outcomes using the SYNTAX score in patients with acute ST-segment elevation myocardial infarction undergoing primary percutaneous coronary intervention: a substudy of the STRATEGY (Single High-Dose Bolus Tirofiban and Sirolimus-Eluting Stent Versus Abciximab and Bare-Metal Stent in Acute Myocardial Infarction) and MULTISTRATEGY (Multicenter Evaluation of Single High-Dose Bolus Tirofiban Versus Abciximab With Sirolimus-Eluting Stent or Bare-Metal Stent in Acute Myocardial Infarction Study) trials.
    Garg S; Sarno G; Serruys PW; Rodriguez AE; Bolognese L; Anselmi M; De Cesare N; Colangelo S; Moreno R; Gambetti S; Monti M; Bristot L; Bressers M; Garcia-Garcia HM; Parrinello G; Campo G; Valgimigli M;
    JACC Cardiovasc Interv; 2011 Jan; 4(1):66-75. PubMed ID: 21251631
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Prehospital versus periprocedural abciximab in ST-elevation myocardial infarction treated by percutaneous coronary intervention.
    Pels K; Schröder J; Witzenbichler B; Müller D; Morguet A; Pauschinger M; Schultheiss HP; Arntz HR
    Eur J Emerg Med; 2008 Dec; 15(6):324-9. PubMed ID: 19078834
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Early administration of intracoronary verapamil improves myocardial perfusion during percutaneous coronary interventions for acute myocardial infarction.
    Hang CL; Wang CP; Yip HK; Yang CH; Guo GB; Wu CJ; Chen SM
    Chest; 2005 Oct; 128(4):2593-8. PubMed ID: 16236929
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Angiographic outcomes in the PLATO Trial (Platelet Inhibition and Patient Outcomes).
    Kunadian V; James SK; Wojdyla DM; Zorkun C; Wu J; Storey RF; Steg PG; Katus H; Emanuelsson H; Horrow J; Maya J; Wallentin L; Harrington RA; Gibson CM
    JACC Cardiovasc Interv; 2013 Jul; 6(7):671-83. PubMed ID: 23866179
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Early treatment with abciximab in patients with ST elevation myocardial infarction results in a high rate of normal or near normal blood flow in the infarct related artery.
    Tödt T; Sederholm-Lawesson S; Stenestrand U; Alfredsson J; Janzon M; Swahn E
    Acute Card Care; 2010 Mar; 12(1):10-7. PubMed ID: 20201657
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Early abciximab administration before transfer for primary percutaneous coronary interventions for ST-elevation myocardial infarction reduces 1-year mortality in patients with high-risk profile. Results from EUROTRANSFER registry.
    Rakowski T; Siudak Z; Dziewierz A; Birkemeyer R; Legutko J; Mielecki W; Depukat R; Janzon M; Stefaniak J; Zmudka K; Dubiel JS; Partyka L; Dudek D
    Am Heart J; 2009 Oct; 158(4):569-75. PubMed ID: 19781416
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 34.